Hepion Pharmaceuticals Files Definitive Proxy Statement

TL;DR

Hepion Pharma filed its proxy statement, get ready for shareholder votes.

AI Summary

Hepion Pharmaceuticals, Inc. filed a Definitive Proxy Statement (DEF 14A) on February 7, 2025. This filing is related to the company's proxy materials, which are typically used for shareholder meetings to vote on corporate matters. The company, formerly known as ContraVir Pharmaceuticals, Inc., is based in Edison, NJ.

Why It Matters

This filing indicates that Hepion Pharmaceuticals is proceeding with corporate governance activities, likely involving shareholder votes on important company decisions.

Risk Assessment

Risk Level: low — A DEF 14A filing is a standard regulatory document for public companies and does not inherently indicate increased risk.

Key Players & Entities

• Hepion Pharmaceuticals, Inc. (company) — Registrant
• ContraVir Pharmaceuticals, Inc. (company) — Former Company Name
• 0001583771 (company) — Central Index Key
• 2834 (company) — Standard Industrial Classification
• 462783806 (company) — IRS Number
• DE (company) — State of Incorporation
• 1231 (company) — Fiscal Year End
• 001-36856 (company) — SEC File Number
• 25599707 (company) — Film Number
• 399 THORNALL STREET (company) — Business Address Street 1

FAQ

Key Financial Figures

• $0.0001 — ce of shares of common stock, par value $0.0001 per share (the “common stock&rdqu

Filing Documents

• formdef14a.htm (DEF 14A) — 390KB
• formdef14a_001.jpg (GRAPHIC) — 6KB
• 0001493152-25-005322.txt ( ) — 399KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 1 5 PROPOSAL 4: PROPOSAL TO APPROVE, FOR PURPOSES OF COMPLYING WITH NASDAQ LISTING RULE 5635(D), THE FULL ISSUANCE OF SHARES OF COMMON STOCK ISSUABLE BY THE COMPANY UPON EXERCISE OF THE SERIES A WARRANTS AND THE SERIES B WARRANTS 17 PROPOSAL 5: APPROVAL OF REVERSE STOCK SPLIT 20

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 27 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 28 OTHER MATTERS 28 iv QUESTIONS AND ANSWERS ABOUT THIS PROXY MATERIAL AND VOTING What is a proxy? A proxy is the legal designation of another person to vote the stock you own. That other person is called a proxy. If you designate someone as your proxy in a written document, that document is also called a proxy or a proxy card. By completing, signing and returning the accompanying proxy card, you are designating John Brancaccio, our Interim Chief Executive Officer and Interim Chief Financial Officer, as your proxy for the Annual Meeting and you are authorizing Mr. Brancaccio to vote your shares at the Annual Meeting as you have instructed them on the proxy card. This way, your shares will be voted whether or not you attend the Annual Meeting. Even if you plan to attend the Annual Meeting, we urge you to vote in one of the ways described below so that your vote will be counted even if you are unable or decide not to attend the Annual Meeting. What is a proxy statement? A proxy statement is a document that we are required by regulations of the Securities and Exchange Commission, or SEC, to give you when we ask you to sign a proxy card designating Mr. Brancaccio as proxy to vote on your behalf. How do I attend the Annual Meeting? The Annual Meeting will be held on March 10, 2025, at 9:00 a.m. local time at the offices of Sheppard Mullin Richter & Hampton, 30 Rockefeller Plaza, New York, NY 10112. Information on how to vote in person at the Annual Meeting is discussed below. Who May Attend the Annual Meeting? Only record holders and beneficial owners of our common stock, or their duly authorized proxies, may attend the Annual Meeting. If your shares of common stock are held in street name, you will need to bring a copy of a brokerage statement or other documentation reflecting your stock ownership as of the Record Date. Who

View Full Filing

View this DEF 14A filing on SEC EDGAR